Monday, June 29, 2020 3:31:25 PM
Infact I took your intial Du errors post and filled in my DD on scientific/medical evidence for my statement of error in generics obviousness story, and Du's shamefaced copying and reiterating a barefaced lie.
Here it is in entirety (was sent to Singer) if anyone wants to go through it, though I recommend a stiff one before ploughing in. "Nullius in verba"
https://documentcloud.adobe.com/link/review?uri=urn:aaid:scds:US:5331b67a-f335-43af-b9c9-a0be2d344e14
When I think of it now and in reflection of all the data, one has to focuses on that key word Obviousness which has been in the English lexicon since the Oxford English Dictionary documents its use in 1663 by the scientist (&Natural Philosopher) Robert Hooke who was the the First President of the Royal Society (the first group of Scientific thinkers using scientific thinking that revolutionized our modern world ..Newton Boyle Hooke...(a great background read is "The Clockwork Universe : Isaac Newton, the Royal Society, and the Birth of the Modern World" by Edward Dolnick Harper Collins).
Hooke says in his preface to his great Magnum Opus Micrographia: "The good success of all these great Men (he cites several great men including Galileo and Harvey), and many others, and the now seemingly great obviousness of most of their and divers other Inventions, which from the beginning of the world have been, as 'twere, trod on, and yet not minded till these last inquisitive Ages."
These precient insights illustrate what we are dealing with: It is likely true there were inadequately done studies (with no placebo controls, no direct comparison of EPA to DHA and inadequate numbers for staistical power or those that studied the wrong TG level population) that showed some suggestion or glimpse that EPA may reduce high TG without LDL elevation buy none showed anything with adequate scientific rigor to conclude anything.So Amarin did the due diligence and went that extra mile to show just that, in completing both MARINE (2011) and ANCHOR (2012) to illustrate that with or without a statin, and in TG>500mg/dl alone or TG (200-500 mg/dl with statin),Vascepa could profoundly reduce TG's, lower LDL, and lower ApoB and that it did so at a very specific dose of 4 g/day and proved it incontrovertibly with a placebo, in adequate staistical power. Who else showed that? No one and the USPTO recognized it fairly:
If Newton wanted to patent his prism for the separartion of light into multiple colors, he might have been rebuffed right away by Judge Du saying it was obvious to do so because so many others did this and that.(could have-should have-would have-people). In fact, Newton being honest admitted as much in writing to Hooke his greatest rival in fame: "What Descartes did was a good step. You have added much several ways, and especially in taking the colours of thin plates into philosophical consideration. If I have seen a little further it is by standing on the shoulders of Giants." could anyone denythat it was Newton who connected the dots, then assembled the facts into a new Law of Light and Optics and found new discovery from the waste of "obviousness", using what eluded others before him? In a final irony, Newton may have borrowed or paraphrased from a thesis on Logic by John salisbury in 1159 called the Metalogicon who said:
"We are like dwarfs sitting on the shoulders of giants. We see more, and things that are more distant, than they did, not because our sight is superior or because we are taller than they, but because they raise us up, and by their great stature add to ours."
It was ever the same, it is so now. It doesn't detract from what Amarin showed convincingly for the first time in MARINE. So now, who will say what is obvious?
">" />
Recent AMRN News
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:31:04 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM